Immobilized sortase enzymes for the Production of Antibody-drug conjugates IMPACT

• Forschungsstelle: INNOSUISSE
• Projektnummer: 25771.1 PFLS-LS
• Projekttitel Englisch: Immobilized sortase enzymes for the production of antibody-drug conjugates

Kurzbeschreibung (Deutsch)

Immobilized sortase enzymes for the Production of Antibody-drug conjugates IMPACT

Kurzbeschreibung (Englisch)

Immobilized sortase enzymes for the production of antibody-drug conjugates

Abstract (Deutsch)

The application of enzymes in continuous production processes is often hindered by the fragility of these natural biocatalysts under operational conditions. In IMPACT, the project partners shall strive to develop a novel nanobiocatalytic material allowing for a drastically enhanced stability of enzymes. The protection strategy relies on the growth, at the surface of immobilized enzymes, of a protective biomimetic layer partially shielding the enzyme. While this layer will provide the enzyme with enhanced resistance to operational stress conditions, its partial nature (i.e. covering only partially the enzyme) will allow the use of this nanomaterial for applications where large substrates are targeted. This is the case in IMPACT as the targeted application is the production of antibody-drug conjugates for use in cancer therapy (multiple myeloma). The project partners shall focus on the development of the nanobiocatalytic material and demonstrate the superiority of the nanobiocatalysts produced as compared to the soluble or immobilized counterparts. In a further phase, the technology developed in IMPACT will be implemented in a flow-through reactor enabling the continuous production of ADCs. Besides the targeted application, IMPACT is expected to open a wealth of new opportunities for the implementation partners for empowering enzymes in different industrial applications.

Abstract (Englisch)

The application of enzymes in continuous production processes is often hindered by the fragility of these natural biocatalysts under operational conditions. In IMPACT, the project partners shall strive to develop a novel nanobiocatalytic material allowing for a drastically enhanced stability of enzymes. The protection strategy relies on the growth, at the surface of immobilized enzymes, of a protective biomimetic layer partially shielding the enzyme. While this layer will provide the enzyme with enhanced resistance to operational stress conditions, its partial nature (i.e. covering only partially the enzyme) will allow the use of this nanomaterial for applications where large substrates are targeted. This is the case in IMPACT as the targeted application is the production of antibody-drug conjugates for use in cancer therapy (multiple myeloma). The project partners shall focus on the development of the nanobiocatalytic material and demonstrate the superiority of the nanobiocatalysts produced as compared to the soluble or immobilized counterparts. In a further phase, the technology developed in IMPACT will be implemented in a flow-through reactor enabling the continuous production of ADCs. Besides the targeted application, IMPACT is expected to open a wealth of new opportunities for the implementation partners for empowering enzymes in different industrial applications.